Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914290 · ClinicalTrials.gov registry record · Phase 2
A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis
A Phase 2 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00914290 is a Phase 2 study that has completed, run by Impax Laboratories. The registered enrollment target is 23 participants.
The verdict
NCT00914290, a Phase 2 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
Interventions
- DRUG Baclofen IR
- DRUG IPX056
- DRUG Placebo IPX056
- DRUG Placebo IR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914290
The ClinicalTrials.gov registry entry for NCT00914290 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Baclofen IR is the first listed.
NCT00914290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914290 about?
NCT00914290 is a clinical study titled "A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis". To explore the safety and efficacy of IPX056 compared with baclofen tablets for alleviation of symptoms of spasticity associated with multiple sclerosis (MS).
What is the current status of trial NCT00914290?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2009-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00914290?
The interventions under investigation include: Baclofen IR (DRUG), IPX056 (DRUG), Placebo IPX056 (DRUG), Placebo IR (DRUG).
Who is sponsoring clinical trial NCT00914290?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.